Dengue Vaccination

Pronounced (den-GEE)

Sanofi-Pasteur will stop manufacturing its dengue vaccine for children. The manufacturer is discontinuing the vaccine citing a lack of demand in the global market to continue production of this vaccine. CDC, in collaboration with the Puerto Rico Department of Health, will continue alerting health professionals about the discontinuation of Dengvaxia and the use of this vaccine as recommended by the Advisory Committee on Immunization Practices (ACIP). Dengvaxia is safe and effective when administered as recommended. There are two other dengue vaccines either approved or in late stages of development. However, they are not currently available in the United States. People can continue to protect themselves and their families from dengue by preventing mosquito bites and controlling mosquitoes in and around their homes.

A vaccine can help prevent dengue, which is caused by four distinct, but closely related dengue viruses, DENV-1, DENV-2, DENV-3, and DENV-4. Only one dengue vaccine is currently available for use:

  • A tetravalent, live-attenuated dengue vaccine (Dengvaxia®)

Dengvaxia will be available starting in 2022 for use in children 9 through 16 years old who have laboratory-confirmed previous dengue virus infection and are living in an area where dengue is endemic (occurs frequently or continuously). Dengue-endemic areas include the U.S. territories of American Samoa, Puerto Rico, and the U.S. Virgin Islands, and freely associated states, including the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.

Talk to your child’s healthcare provider if you have questions about the dengue vaccine.